In a multicenter international registry, Paolisso et al. [120] evaluated the effects of SGLT2 inhibitors in 311 patients with type 2 diabetes, severe AS, LVEF < 50%, and extra-valvular cardiac damage (EVCD) undergoing TAVI. This evidence concerns the gene SLC5A2 and aortic valve stenosis.